Stockreport

Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders [Seeking Alpha]

Nkarta, Inc.  (NKTX) 
PDF Financially healthy, with a high current ratio and a cash runway extending into 2026, indicating low near-term dilution risk. Despite high short interest, market sent [Read more]